FIELD: biotechnology, peptides.
SUBSTANCE: invention relates to preparing conjugates of polypeptides with polyethylene glycol. Mutant peptide possessing the G-CSF activity is prepared by changes of above 15 amino acid residues in definite positions of amino acid sequence in G-CSF of wiled type with lysine residue mainly. Then the prepared mutant peptide G-CSF is conjugated with a polyethylene glycol (PEG) molecule. Invention provides increasing a half-life value and enhancing the biological activity of G-CSF in vivo as compared with the native non-conjugated G-CSF of wild type. Invention can be used in preparing conjugates of mutant form of G-CSF with PEG.
EFFECT: improved preparing method.
15 cl, 3 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULES SIMILAR TO FACTOR VII OR VIIA | 2001 |
|
RU2278123C2 |
| INTERFERON-GAMMA CONJUGATES | 2000 |
|
RU2268749C2 |
| NEW VERSION OF EXENDIN OR ITS CONJUGATE | 2010 |
|
RU2528734C2 |
| G-CSF CONJUGATES | 2002 |
|
RU2307126C2 |
| VARIANTS OF GAMMA-INTERFERON POLYPEPTIDE | 2002 |
|
RU2296130C2 |
| GLYCO-PEG GRANULOCYTE COLONY-STIMULATING FACTOR | 2004 |
|
RU2400490C2 |
| PRODUCTION OF POLYPEPTIDE CONJUGATED WITH POLY(ETHYLENEGLYCOL) FRAGMENT, NUCLEIC ACID AND FUSED POLYPEPTIDE MEANT FOR APPLICATION WITH THIS PROCESS | 2011 |
|
RU2584572C2 |
| PROTEIN COMPLEX, OBTAINED BY USING FRAGMENT OF IMMUNOGLOBULIN, AND METHOD OF SUCH COMPLEX OBTAINING | 2004 |
|
RU2356909C2 |
| CONJUGATED FACTOR VIII MOLECULES | 2009 |
|
RU2573587C2 |
| CONJUGATE OF FACTOR VII POLYPEPTIDE, METHOD OF OBTAINING IT, ITS APPLICATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2003 |
|
RU2362807C2 |
